The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patients by Brynildsen, Jon et al.
Contents lists available at ScienceDirect
Clinical Biochemistry
journal homepage: www.elsevier.com/locate/clinbiochem
The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac
surgical patients
Jon Brynildsena,b,1, Liisa Petäjäc,1, Ville Pettiläd,e, Ståle Nygårdf, Suvi T. Vaarad, Rita Linkod,
Marjatta Okkonend, Tor-Arne Hagveg,h, Leena Soininend, Raili Suojaranta-Ylinenc,
Magnus Nakrem Lyngbakkena,b, Torbjørn Omlanda,b, Helge Røsjøa,b,⁎
a Division of Medicine, Akershus University Hospital, Lørenskog, Norway
b Center for Heart Failure Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
c Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
d Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki, Helsinki University Hospital, Helsinki,
Finland
e Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
f Bioinformatics Core Facility, Institute for Medical Informatics, Oslo University Hospital, University of Oslo, Oslo, Norway
g Division of Diagnostics and Technology, Akershus University Hospital, Lørenskog, Norway
h Institute of Clinical Medicine, University of Oslo, Oslo, Norway
A R T I C L E I N F O
Keywords:
Biomarkers
Cardiac surgery
Troponin T
NT-proBNP
Risk assessment
A B S T R A C T
Background: European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) is used for risk strati-
fication before cardiac surgery, but whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-
sensitivity troponin T (hs-TnT) may add prognostic information to EuroSCORE II is not known.
Methods: Preoperative (n = 640) and postoperative (n = 629) blood samples were available from cardiac sur-
gical patients with 961-day follow-up (FINNAKI Heart study; cohort #1). The accuracy of a parsimonious risk
model with NT-proBNP measurements was also tested in 90 patients with respiratory failure after cardiac sur-
gery (FINNALI study; cohort #2).
Results: Sixty-one patients (9.5%) died during follow-up in cohort #1. Preoperative NT-proBNP and hs-TnT
concentrations correlated (rho = 0.58; p < 0.001) and were higher in non-survivors compared to survivors:
median 2027 (Q1-3 478-5387) vs. 373 (134–1354) ng/L [NT-proBNP] and 39 (16–191) vs. 13 (8–32) ng/L [hs-
TnT]; p < 0.001 for both. Preoperative NT-proBNP concentrations were associated with time to death after
adjustment for EuroSCORE II (HR [lnNT-proBNP] 1.33 [95% CI 1.08–1.64]), p = 0.008 and reclassified patients
on top of EuroSCORE II (net reclassification index 0.39 [95% CI 0.14–0.64], p = 0.003). Pre- and postoperative
NT-proBNP concentrations were closely correlated (rho = 0.80, p < 0.001) and postoperative NT-proBNP
concentrations were also associated with long-term mortality after adjustment for EuroSCORE II. A parsimonious
risk model that included age, creatinine clearance, chronic pulmonary disease, and NT-proBNP measurements
provided comparable prognostic accuracy as EuroSCORE II in cohort #1 and #2 for risk of long-term mortality.
hs-TnT measurements did not add to NT-proBNP measurements
Conclusion: NT-proBNP measurements could improve and simplify risk prediction in cardiac surgical patients.
1. Introduction
Patients that are scheduled for cardiac surgery constitute a
heterogeneous group with increased mortality compared to subjects of
the general population [1–3]. Accordingly, the European System for
Cardiac Operative Risk Evaluation (EuroSCORE) risk model was
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developed to provide prognostic information concerning hospital
mortality in cardiac surgical patients [4]. Later, this model has been
revised as EuroSCORE II [5] and EuroSCORE II has also been validated
to provide long-term risk prediction after isolated coronary artery by-
pass graft (CABG) surgery [6]. The EuroSCORE II score is calculated
based on 18 variables, including age, gender and specific comorbidities,
indices for functional status, estimated risk for the specific surgical
procedure, and indices for cardiac function. Although recent myo-
cardial infarction and measurements of left ventricular ejection fraction
are included in EuroSCORE II to reflect cardiac status, circulating car-
diac biomarkers are currently not included in risk models for cardiac
surgical patients [5].
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-
sensitivity troponin T (hs-TnT) are established cardiac biomarkers in
routine clinical use in Europe [7,8]. NT-proBNP has an ability to dis-
criminate between heart failure and non-cardiac dyspnea [9], while
cardiac troponin is a sine qua non criterion to diagnose myocardial
infarction in patients with acute coronary syndromes [7]. Circulating
concentrations of NT-proBNP and hs-TnT have also been reported to
provide incremental prognostic information to clinical risk indices
across the spectrum of cardiovascular disease [8,10], including in car-
diac surgical patients [11–14] and in patients with intermediate Euro-
SCORE II risk score [15]. We have also recently reported that the
combination of pre- and postoperative hs-TnT concentrations provided
additional prognostic information to EuroSCORE II in patients with
non-CABG cardiac surgery in the FINNish Acute Kidney Injury (FIN-
NAKI) Heart Study [16]. Still, whether NT-proBNP or the combination
of NT-proBNP and hs-TnT measurements adds prognostic information
to EuroSCORE II, including reclassification, is currently not known.
This information should be of clinical relevance as EuroSCORE II have
suboptimal performance in high-risk patients and in patients subjected
to isolated CABG surgery [17,18], which supports the call for variables
for a new and improved EuroSCORE III risk model [5]. Accordingly, in
this study we hypothesized that (1) NT-proBNP and hs-TnT measure-
ments would improve the EuroSCORE II risk model, as assessed by
several statistical metrics, and (2) that a risk model with fewer key
clinical variables and cardiac biomarkers (parsimonious risk model)
could provide comparable prognostic information to the EuroSCORE II
risk model.
2. Methods
2.1. Cohort #1: FINNAKI Heart Study
The FINNAKI Heart Study is a single-center sub-study of the mul-
ticenter FINNAKI Study [16,19]. The FINNAKI Heart Study is a pro-
spective observational study with an overall aim to evaluate the pre-
dictive value of cardiac biomarkers for all-cause mortality in patients
subjected to cardiac surgery. The Ethics Committee in Helsinki Uni-
versity Hospital approved the study and informed consent was obtained
from each patient or their next of kin. The flow chart of patient inclu-
sion is presented in Fig. 1. All adult patients (≥18 years) subjected to
cardiac surgery in Helsinki University Hospital from September 1st
2011 to January 31st 2012 were eligible for inclusion into the study,
except some predefined groups: patients planned for cardiac trans-
plantation, patients that refused transfusions, and patients that were
scheduled for implantation of ventricular assist devices or trans-femoral
valve implantations. We also excluded patients that were not admitted
to Intensive Care Units (ICUs) after surgery, non-Finnish residents,
patients without informed consent, and patients without preoperative
blood sampling.
Between February 1st 2012 and June 20th 2012 the FINNAKI Heart
Study only included patients undergoing CABG. The endpoint of this
study was all-cause mortality and maximum follow-up was 961 days.
Demographic and clinical data were prospectively collected to the
Finnish Intensive Care Consortium database (Tieto Ltd., Helsinki,
Finland) via study-specific case report forms and electronic anesthesia
and intensive care patient reports (PICIS, Wakefield, MA, USA and
Dräger Medical, Lübeck, Germany). Creatinine clearance was calcu-
lated according to the Cockcroft-Gault formula for EuroSCORE II [5].
Mortality data were obtained from the Finnish Population Register
Centre and no patient was lost to follow-up.
2.2. Cohort #2: cardiac surgical patients in the FINNALI study
The FINNish Acute Lung Injury (FINNALI) Study was a prospective
observational multicenter study conducted during an 8-week period
from April 16th 2007 to June 10th 2007, which enrolled patients
treated for at least 6 h with ventilatory support in 25 Finnish ICUs
(Supplementary Fig. 1) [20]. For this study, we included only patients
from the FINNALI Study that underwent cardiac surgery prior to the
need for ventilatory support and with blood sampling on ICU admis-
sion, entailing the five Finnish University Hospitals and Vasa Central
Hospital (Supplementary Fig. 1; n = 90). Mean follow-up was 331 days
(± 10.69 days [SEM]) and maximal follow-up was 365 days in cohort
#2. Data for all-cause mortality in cohort #2 was obtained from Sta-
tistics Finland. We recorded information on comorbidities and standard
laboratory variables from the patient chart records. The FINNALI Study
was conducted according to the Declaration of Helsinki and the ethical
consideration and approval from the Helsinki University Ethics Com-
mittee covered all hospitals included in the study. All patients or a close
relative gave informed consent before study commencement.
2.3. Blood sampling and biochemical analysis
Blood samples in cohort #1 were collected from arterial lines before
induction of anesthesia and on the first postoperative morning. The
samples were separated and stored at−80 °C, and shipped on dry ice to
Akershus University Hospital for hs-TnT and NT-proBNP analyses. Due
to the inclusion strategy of cohort #2 that required respiratory failure,
only blood samples on day 1 after cardiac surgery were available in the
FINNALI Study. These were stored for a short period at −20 °C or
colder in each of the participating hospitals before being moved to
Helsinki University Central Hospital and stored at −80 °C before NT-
proBNP measurements. In both studies the methods for storing blood
Fig. 1. Flowchart FINNAKI Heart Study (cohort #1).
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samples have been shown to be adequate for stability in later analyses
[21–23]. hs-TnT concentrations in cohort #1 were determined on the
auto-analyzer Cobas 8000 e801 (Roche Diagnostics) by a commercial
assay (troponin T hs STAT, Roche Diagnostics). The lower detection
limit is 5 ng/L, limit of blank is 3 ng/L, and the 99th percentile value in
healthy subjects is 14 ng/L with a coefficient of variation (CV) of 8% for
the hs-TnT assay [24,25]. Fifteen patients had missing preoperative hs-
TnT concentrations and one patient had hs-TnT concentration below
the limit of blank and was assigned a concentration of 3 ng/L. NT-
proBNP concentrations in cohort #1 were measured by the commer-
cially available immunometric assay (proBNP, Roche Diagnostics) on a
Cobas 8000 e801 (Roche Diagnostics), while for cohort #2 NT-proBNP
concentrations were measured by a commercially available im-
munoassay (proBNP, Roche Diagnostics) on an Elecsys 2010 auto-
analyzer (Roche Diagnostics) as previously described [26]. Specimens
were run in one batch when analyzed.
2.4. Statistics
We report continuous variables with non-normal distribution as
median (quartile 1–3), and categorical variables are presented as ab-
solute number (percentage). We tested the distribution of continuous
variables by the Kolmogorov-Smirnov test. To compare continuous
variables we used the Mann-Whitney U test and categorical data were
compared by the Pearson Chi-Square test or the Fisher's exact test.
Serial measurements were tested by the related-samples Wilcoxon
signed rank test. We calculated correlation coefficients by Spearman
rank correlation and explored variables associated with high pre-
operative hs-TnT and NT-proBNP concentrations by linear regression
analyses.
To assess the association between preoperative hs-TnT and NT-
proBNP concentrations and time to death in cohort #1, we stratified
patients according to biomarker quartiles in Kaplan-Meier plots and
compared the groups by the log-rank test. We also performed univariate
and multivariate Cox proportional hazard regression analyses for
follow-up data after discharge from hospital.
In the multivariate regression models regarding prognosis, all
variables associated with mortality in the univariate analyses were in-
cluded into the multivariate models (backward selection) except in-
dividual covariates of EuroSCORE II or variables covered by
EuroSCORE II, as EuroSCORE II score was included in all multivariate
analyses. For each variable that was included in the Cox multivariate
analyses there were> 8 events and thus overfitting should not be a
problem in our analyses [27].
Prognostic accuracy was also assessed by receiver operating char-
acteristic (ROC) analysis and presented as area under the curve (AUC)
with 95% confidence intervals (CI). Data from nested models are pre-
sented as recently recommended [28]. We determined the optimal pre-
and postoperative NT-proBNP concentration for assessing long-term
mortality from ROC-AUC statistics and by the use of the Youden index
J. We also explored whether preoperative hs-TnT and NT-proBNP
concentrations, separately and in combination, could add to Euro-
SCORE II for the prediction of postoperative death by calculating the
category-free net reclassification index (NRI) [29].
A parsimonious risk model means a model that has been reduced
e.g. by stepwise elimination procedure, resulting in a model with a
limited number of variables. To develop a parsimonious risk model for
cardiac surgical patients, we first calculated ROC-AUC in cohort #1 of
all variables included in the EuroSCORE II individually, biomarkers
individually, as well as the total EuroSCORE II regarding long-term
mortality in the FINNAKI Heart Study (cohort #1). Second, we ar-
ranged combinations of 2, 3, and 4 variables in cohort #1 to identify
the combination that gave the highest AUC using lasso regression [30].
We used the 4-unit combination with the highest AUC to create pre- and
postoperative Cardiac Surgery Biomarker Scores and we tested the
ROC-AUC of the postoperative Cardiac Surgery Biomarker Score in
Table 1
Baseline characteristics according to long-term survival status of cardiac surgical patients
from the FINNAKI Heart Study (cohort #1).
Survivors Non-survivors P value
(N = 579,
90.5%)
(N = 61, 9.5%)
Age (years) [0] 67.0 (59.0–74.0) 75.0 (65.5–80.0) < 0.001
Female sex [1] 143 (24.7%) 18 (29.5%) 0.415
Body mass index (m/kg2) [0] 27.1 (24.2–30.5) 25.4 (23.2–30.4) 0.09
LVEF (%) [0] < 0.001
< 21 2 (0.3%) 2 (3.3%)
21–30 19 (3.3%) 6 (9.8%)
31–50 126 (21.8%) 19 (31.1%)
≥50 432 (74.6%) 34 (55.7%)
NYHA Functional Class [0] 0.001
4 139 (24.0%) 26 (42.6%)
3 207 (35.8%) 25 (41.0%)
2 187 (32.3%) 10 (16.4%)
1 46 (7.9%) 0 (0.0%)
CCS Class 4 angina [0] 174 (30.2%) 26 (42.6%) 0.044
Estimated creatinine clearance
(ml/min) [3]
83.2
(66.2–109.4)
64.0 (44.9–82.7) < 0.001
Smoking status [6] 0.51
Smoker 84 (14.6%) 13 (21.3%)
Ex-smoker 126 (21.9%) 13 (21.3%)
Non-smoker 251 (43.7%) 21 (34.4%)
Smoking status unknown 112 (19.5%) 14 (23%)
History of:
Hypertension [0] 370 (63.9%) 45 (73.8%) 0.125
Heart failure [2] 86 (14.9%) 21 (34.4%) < 0.001
Peripheral vascular disease
[0]
88 (15.2%) 17 (27.9%) 0.011
Pulmonary disease [0] 49 (8.5%) 14 (23.0%) < 0.001
Insulin-dependent diabetes
mellitus [0]
52 (9.0%) 10 (16.4%) 0.063
Non-insulin-dependent
diabetes mellitus [0]
102 (17.6%) 8 (13.1%) 0.375
Recent AMI [0] 187 (32.3%) 26 (42.6%) 0.104
Prior cardiac surgery [0] 21 (3.6%) 3 (4.9%) 0.492
Pulmonary hypertension
(mmHg) [0]
< 0.001
< 31 378 (65.3%) 20 (32.8%)
31–55 175 (30.2%) 28 (45.9%)
> 55 26 (4.5%) 13 (21.3%)
Active endocarditis [0] 9 (1.6%) 2 (3.3%) 0.283
Chronic renal disease [6] 57 (9.9%) 15 (25.0%) < 0.001
Chronic liver disease [3] 3 (0.5%) 3 (4.9%) 0.001
Poor mobility [0] 10 (1.7%) 4 (6.6%) 0.036
Urgency: [0] 0.003
Elective 350 (60.4%) 29 (47.5%)
Urgent 189 (32.6%) 23 (37.7%)
Emergency 40 (6.9%) 8 (13.1%)
Salvage 0 (0.0%) 1 (1.6%)
Cardiogenic shock at
admission/prior to
surgery [0]
11 (1.9%) 5 (8.2%) < 0.003
Assisted vent. in use before
surgery [5]
24 (4.2%) 10 (16.7%) < 0.001
Intra-aortic balloon pump [5] 14 (2.4%) 2 (3.3%) 0.657
Critical preoperative state [0] 40 (6.9%) 13 (21.3%) < 0.001
Weight of intervention [0] 0.11
Isolated CABG 383 (66.1%) 33 (54.1%)
Single non-CABG 98 (16.9%) 14 (23.0%)
Two procedures 79 (13.6%) 9 (14.8%)
Three or more procedures 19 (3.3%) 5 (8.2%)
Preoperative values:
hs-TnT (ng/L) [15] 13 (8–32) 39 (16–191) < 0.001
NT-proBNP (ng/L) [0] 373 (134–1354) 2027
(478–5387)
< 0.001
EuroSCORE II (%) [0] 2.1 (1.2–4.1) 6.7 (2.9–15.8) < 0.001
Perioperative values:
Aortic occlusion time (min)
[0]
65.0 (50.0–90.0) 59.0 (35.5–82.0) 0.07
Cardio-pulmonary-bypass
time (min) [0]
93.0
(72.0–125.0)
90.0
(69.5–120.5)
0.83
(continued on next page)
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cohort #2 for external validation. Data were considered significant with
a two-sided P value of< 0.05. Statistical analyses were performed
using IBM SPSS Statistics 22 and 24 (IBM Corp, Armonk, NY, USA),
MedCalc Statistical Software version 14.10.2 (MedCalc Software, Os-
tend, Belgium), and the statistical programming language R (R Foun-
dation for Statistical Computing, Vienna, Austria).
3. Results
3.1. FINNAKI Heart Study: baseline characteristics
Of the 640 patients included in cohort #1, 416 patients (65%) un-
derwent isolated CABG, 112 patients (17.5%) single non-CABG surgery,
88 patients (13.8%) underwent two procedures, and 24 patients (3.8%)
were subjected to three or more procedures (Supplementary Table 1).
In total, 61 patients (9.5%) died within 961 days after surgery (Fig. 1).
Baseline characteristics with patients stratified according to mortality
are presented in Table 1. Non-survivors in cohort #1 were older, had
more frequent and severe cardio-pulmonary disease, reduced renal
function, and more often underwent acute surgery compared to patients
surviving beyond 961 days after surgery. EuroSCORE II, preoperative
NT-proBNP and hs-TnT concentrations, and postoperative NT-proBNP
concentrations were all significantly higher in long-term non-survivors
compared to survivors. Type of surgical procedure did not differ be-
tween long-term survivors and non-survivors (Supplementary Table 1;
p = 0.11).
3.2. Cardiac biomarker concentrations in cardiac surgical patients: cohort
#1
Preoperative NT-proBNP and hs-TnT concentrations correlated
(rho = 0.58; p < 0.001) and medians [quartile 1–3] were 439
(148–1574) ng/L and 15 (8–37) ng/L, respectively, in the FINNAKI
Heart Study (cohort #1). In multivariate linear regression analyses that
explained 61% of the variance in preoperative NT-proBNP concentra-
tions (r2 = 0.61), several factors were associated with high NT-proBNP
concentrations, including critical preoperative state and the weight of
the intervention (CABG vs. other cardiac surgery) (Supplementary
Table 2). High preoperative hs-TnT concentrations were also associated
with a number of variables in multivariate linear regression analysis,
including recent acute myocardial infarction, surgical urgency, critical
preoperative state, weight of the intervention, and preoperative NT-
proBNP concentration (r2 = 0.58; Supplementary Table 3).
Postoperative NT-proBNP and hs-TnT concentrations in the
FINNAKI Heart Study were 1352 (677–2853) ng/L and 451 (268–894)
ng/L, respectively. Both values were significantly higher than
preoperative concentrations (p < 0.001). We found significant corre-
lations between pre- and postoperative concentrations for both NT-
proBNP (rho = 0.80, p < 0.001) and hs-TnT (rho = 0.27,
p < 0.001), and postoperative NT-proBNP and hs-TnT concentrations
were also correlated (rho = 0.42, p < 0.001). Duration of cardiac
surgery and some of the same clinical variables that influenced pre-
operative measurements were also associated with postoperative NT-
proBNP and hs-TnT concentrations (Supplementary Tables 4 and 5).
3.3. FINNAKI Heart Study: cardiac biomarker concentrations and mortality
Kaplan-Meier plots with biomarker concentrations divided into
quartiles, NT-proBNP (ng/L) [Q1 < 148, Q2 148–438, Q3 439–1574,
Q4 > 1574] and hs-TnT (ng/L) [Q1 < 8.1, Q2 8.1–14.7, Q3
14.7–37.1, Q4 > 37.1], demonstrate that patients with preoperative
NT-proBNP and hs-TnT concentrations in the 4th quartile had increased
mortality during 961-day follow-up (Fig. 2; p < 0.001 with the log-
Table 1 (continued)
Survivors Non-survivors P value
(N = 579,
90.5%)
(N = 61, 9.5%)
Surgery on thoracic aorta
[1]
37 (6.4%) 1 (1.7%) 0.24
Postoperative values:
hs-TnT (ng/L) [11] 439 (267–866) 576 (296–1182) 0.09
NT-proBNP (ng/L) [11] 1269
(646–2559)
2913
(1213–8951)
< 0.001
AMI, Acute Myocardial Infarction; CABG, Coronary Artery Bypass Graft; CCS Class 4,
Canadian Cardiovascular Society Class 4; EuroSCORE II, European System for Cardiac
Operative Risk Evaluation II; hs-TnT, high-sensitivity Troponin T; LVEF, Left Ventricular
Ejection Fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New
York Heart Association.
Continuous variables are presented as median (IQR). Categorical variables are presented
as counts (percentage).
Numbers of patients with missing data in brackets.
Fig. 2. Kaplan-Meier survival plots divided by quartiles of (A) preoperative NT-proBNP
concentrations (ng/L) [Q1 < 148, Q2 148–438, Q3 439–1574, Q4 > 1574] and (B) hs-
TnT concentrations (ng/L) [Q1 < 8.1, Q2 8.1–14.7, Q3 14.7–37.1, Q4 > 37.1].
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rank test for both). In univariate Cox regression analyses, both pre-
operative NT-proBNP and hs-TnT concentrations were significantly
associated with time to death in 961 days, while only preoperative NT-
proBNP concentrations provided additional prognostic information to
EuroSCORE II (Table 2). The optimal preoperative NT-proBNP con-
centration for assessing long-term risk was 1170 ng/L with sensitivity
66% (95% CI 52–77%), specificity 73% (69–77%), positive likelihood
ratio 2.5 (2.0–3.1) and negative likelihood ratio 0.5 (0.3–0.7). For
postoperative NT-proBNP the optimal cut-off was 1834 ng/L with sen-
sitivity 70% (56–81%), specificity 66% (62–70%), positive likelihood
ratio 2.1 (1.7–2.5), and negative likelihood ratio 0.5 (0.3–0.7).
Exploring hs-TnT and NT-proBNP in separate multivariate Cox re-
gression analyses did not change the results (Supplementary Table 6).
The ROC-AUC of preoperative NT-proBNP concentrations to predict
961-day mortality was 0.734 (95% CI 0.668–0.800), the AUC of
EuroSCORE II was 0.740 (0.672–0.807), and the AUC of preoperative
NT-proBNP and EuroSCORE II was 0.762 (0.699–0.826). Preoperative
NT-proBNP concentrations also reclassified a significant proportion of
patients when added to EuroSCORE II with 388 patients being moved to
a more correct risk stratum (61%), while NT-proBNP measurements
failed to improve risk assessment in 252 patients: NRI = 0.39 (95% CI
0.14–0.64), p = 0.003. Hence, preoperative NT-proBNP concentrations
moved patients that did not experience an event down in risk stratum
and moved patients that experienced an event up in risk stratum when
added on top of EuroSCORE II (Fig. 3). In contrast, the addition of hs-
TnT to EuroSCORE II did not improve risk prediction as tested by NRI
(0.09 [−0.11–0.29, p = 0.37]) and the AUC of preoperative hs-TnT
measurements was 0.700 (0.631–0.769).
Assessing also postoperative cardiac biomarker concentrations, only
NT-proBNP concentrations were associated with long-term mortality
when measured day 1 after cardiac surgery (Table 1 and Supplementary
Fig. 2). The ROC-AUC of postoperative NT-proBNP concentrations to
separate long-term survivors from non-survivors was 0.711
(0.693–0.782) and the AUC of postoperative hs-TnT concentrations was
0.566 (0.485–0.648). Postoperative NT-proBNP concentrations were
also significantly associated with long-term outcome in multivariate
analysis that included EuroSCORE II, while postoperative hs-TnT did
not provide additional prognostic information to EuroSCORE II in the
total cohort (Supplementary Table 7).
3.4. Cardiac surgery biomarker score: parsimonious risk model
Twelve of the eighteen variables included in the EuroSCORE II
calculations were associated with mortality in the FINNAKI Heart Study
when analyzed separately (cohort #1; Supplementary Table 8). The 4-
variable combination with the highest ROC-AUC for 961-day mortality
in cohort #1 included (1) preoperative NT-proBNP concentrations, (2)
age, (3) estimated creatinine clearance, and (4) history of chronic
pulmonary disease. This parsimonious Cardiac Surgery Biomarker
Score yielded an AUC of 0.787 (0.726–0.848) for all-cause mortality in
cohort #1. The corresponding AUC of EuroSCORE II for 961-day mor-
tality was 0.744 (0.676–0.811). Calculating the AUC for the Cardiac
Surgery Biomarker Score using postoperative instead of preoperative
NT-proBNP yielded an AUC of 0.766 (0.699–0.832) in cohort #1 and an
AUC of 0.819 (0.613–1.00) for all-cause mortality in cohort #2.
Baseline characteristics of cardiac surgical patients in cohort #2 are
presented in Supplementary Table 9.
4. Discussion
In this prospective observational study comprising two separate
cohorts of critically ill patients after cardiac surgery we found that NT-
proBNP measurements had predictive value for time to death. A 4-item
Cardiac Surgery Biomarker Score including NT-proBNP measurements
also had at least comparable discriminative value as the 18-item
EuroSCORE II for long-term risk of death.
The original EuroSCORE was created as a risk prediction tool for
hospital mortality following cardiac surgery [4]. However, as the ma-
jority of cardiac surgical patients die after hospital discharge [2], the
original EuroSCORE was later proven useful also to predict long-term
mortality [31,32]. EuroSCORE II was subsequently developed and
found superior to the original EuroSCORE risk model [33,34]. How-
ever, there are some obvious limitations to EuroSCORE II, including the
Table 2
Predictive factors for time to death in in 961 days by univariate and multivariate Cox
proportional hazard regression.
961 days
HR 95% CI P value Wald
Univariate analysis
Age (per one year)a 1.07 1.04–1.10 < 0.001 21.7
Female sexa 1.27 0.73–2.20 0.40 0.7
Body mass index (m/kg2) 0.96 0.91–1.02 0.18 1.8
LVEF (≥ 50%)a 0.45 0.27–074 0.002 9.8
NYHA functional class (≥ 3)a 3.30 1.67–6.49 0.001 11.8
CCS class 4 anginaa 1.69 1.02–2.81 0.042 4.1
Estimated creatinine clearance (per
one unit)a,b
0.21 0.12–0.36 < 0.001 31.1
Smoking (current/ex-smoker) 1.27 0.77–2.11 0.36 0.9
History of:
Hypertension 1.56 0.88–2.76 0.13 2.3
Heart failure 2.81 1.66–4.77 < 0.001 14.7
Peripheral vascular diseasea 2.07 1.18–3.62 0.011 6.5
Pulmonary diseasea 2.96 1.63–5.39 < 0.001 12.7
Insulin-dependent diabetes mellitusa 1.91 0.97–3.76 0.061 3.5
Non-insulin-dependent diabetes
mellitus
0.71 0.34–1.49 0.36 0.8
Recent AMIa 1.54 0.93–2.55 0.10 2.8
Previous cardiac surgerya 1.37 0.43–4.37 0.60 0.3
Pulmonary arterial pressure (mmHg)a
31-55c 2.91 1.64-5.17 < 0.001 13.4
> 55c 7.84 3.90-15.8 < 0.001 33.4
Active endocarditisa 2.14 0.52–8.77 0.29 1.1
Chronic renal disease 2.73 1.52–4.90 < 0.001 11.4
Chronic liver disease 7.03 2.20–22.48 0.001 10.8
Poor mobilitya 3.64 1.32–10.05 0.012 6.2
Urgency (elective vs acute)a 1.65 0.999–2.73 0.05 3.8
Cardiogenic shock at admission/prior
to surgery
4.07 1.63–10.16 0.003 9.0
Assisted vent. in use before surgery 4.21 2.13–8.30 < 0.001 17.2
Intra-aortic balloon pump 1.38 0.34–5.65 0.66 0.2
Critical preoperative statea 3.46 1.87–6.38 < 0.001 15.7
Weight of intervention
(isolated CABG vs other card
surg)a
0.63 0.38–1.05 0.08 3.1
Preoperative values:
hs-TnT (per one unit)b 1.34 1.20–1.51 < 0.001 25.6
NT-proBNP (per one unit)b 1.68 1.43–1.97 < 0.001 41.0
EuroSCORE II (per one unit)b 2.13 1.73–2.62 < 0.001 50.9
Perioperative values:
Aortic occlusion time (min) 0.995 0.988–1.002 0.16 2.0
Cardio-pulmonary-bypass time (min) 1.00 0.996–1.005 0.94 0.01
Surgery on thoracic aortaa 0.26 0.04–1.84 0.18 1.8
Multivariate analysis: NT-proBNPd
EuroSCORE II (per one unit)b 1.63 1.24–2.16 0.001 11.92
NT-proBNP (per one unit)b 1.32 1.07–1.63 0.009 6.83
AMI, Acute Myocardial Infarction; CABG, Coronary Artery Bypass Graft; CCS Class 4,
Canadian Cardiovascular Society Class 4; CI, Confidence Interval; EuroSCORE II,
European System for Cardiac Operative Risk Evaluation II; hs-TnT, high-sensitivity
Troponin T; HR, Hazard Ratio; LVEF, Left Ventricular Ejection Fraction; NT-proBNP, N-
terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
a Part of the EuroSCORE II calculations.
b Estimated creatinine clearance, NT-proBNP, hs-TnT and EuroSCORE II were trans-
formed with natural logarithm before regression analysis because of non-normal dis-
tribution.
c Compared to< 31 mm Hg.
d Variables retained in the final model with preoperative NT-proBNP and preoperative
variables not included in the EuroSCORE II model or covered by variables in ESII model
(−2 log likelihood = 727).
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need to collect data on 18 variables. Moreover, EuroSCORE II also in-
cludes invasive pulmonary pressure measurements, which limits the
usefulness of this model for preoperative risk assessment. EuroSCORE II
is neither validated for use in patients older than 90 years [5], and some
recommend that EuroSCORE II should not be used in patients over
70 years [35]. Recent studies have also questioned the accuracy of
EuroSCORE II in patients subjected to isolated CABG and in high-risk
patient groups [17,18].
Cardiac biomarkers have obtained a strong position in clinical car-
diology, including the potential of NT-proBNP to improve risk predic-
tion in cardiac surgical patients [11–13,15]. We now validate and ex-
tend these previous data by demonstrating that pre- and postoperative
NT-proBNP measurements provide incremental prognostic information
to EuroSCORE II in cardiac surgical patients. Accordingly; we believe
NT-proBNP should be included in a revised EuroSCORE III risk model.
Pertinent to this point; we also demonstrate that a 4-item Biomarker
Risk Score of age, estimated creatinine clearance, history of chronic
pulmonary disease, and NT-proBNP measurements provide at least
comparable prognostic information as the 18-item EuroSCORE II for
long-term risk prediction in cardiac surgical patients. Thus, although
this Biomarker Risk Score will need validation in other external cohorts,
our data suggest that NT-proBNP measurements could also simplify risk
assessment in cardiac surgical patients. As NT-proBNP primarily is
considered a marker of cardiomyocyte stress and heart failure devel-
opment, it is possible also that stringent postoperative control of sub-
jects with high NT-proBNP concentration could help reduce heart
failure-related mortality during follow-up in cardiac surgical patients.
In contrast, hs-TnT measurements did not improve risk assessment on
top of EuroSCORE II in our cardiac surgical patients. Of note, perio-
perative NT-proBNP measurement is also recommended to improve risk
assessment in selected groups of patients undergoing noncardiac sur-
gery [36]. We have not directly tested whether BNP measurements
would have provided similar results as NT-proBNP in our study, but in
general these two assays for pro-B-type natriuretic peptide measure-
ment are considered equal [37] and it is plausible that also BNP mea-
surements would have added prognostic information to EuroSCORE II
in our cohort.
4.1. Strengths and limitations
This study has some limitations and strengths. First, the FINNAKI
Heart Study only included patients from only one tertiary cardiac sur-
gery center and therefore our data will need validation in additional
cohorts. Second, we included different types of cardiac surgical patients
into these analyses, although the majority of patients were subjected to
CABG. Finally, external validation of preoperative NT-proBNP mea-
surements is also needed for the Cardiac Surgery Biomarker Score,
however, it is promising that it performed well with postoperative NT-
proBNP in cohort #2. Potential strengths of the study include the use of
contemporary biomarker assays, comprehensive statistical analyses
according to established guidelines for biomarker studies [38], and
benchmarking with the EuroSCORE II model.
5. Conclusion
We found that pre- and postoperative NT-proBNP measurements
add to EuroSCORE II for risk prediction in cardiac surgical patients. A 4-
item Cardiac Surgery Biomarker Score with NT-proBNP measurements
could also simplify long-term risk prediction in cardiac surgical pa-
tients.
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